TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal®
Study: NCT01763008

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
Study: NCT02035254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Wellness Program
Description: Web-based educational modules and physical activity and/or health weight challenges

Intervention type: OTHER
Group type: OTHER
Intervention: Web-based Wellness Program
Description: Web-based educational modules and physical activity and/or health weight challenges
Study: NCT04103580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo elicitation
Description: Caregivers are taught to use photos to illustrate various feelings and meanings
Study: NCT03407716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Correlative studies
Study: NCT03878641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children in Grade 1 to 5 with literacy and language needs
Description: The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
Study: NCT02869659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Group
Description: All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Weight Loss
Description: 18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
Study: NCT02569099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver training
Description: One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
Study: NCT02551042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin®P, coagulation factor XIII concentrate (Human)
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: IV infusion
Study: NCT00963118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant based nutrition bar
Description: Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
Study: NCT00003745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT02894268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100g po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 20mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 20mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Subcitrate
Description: Bismuth 20mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Subcitrate
Description: Bismuth 20mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensitivity antibiotics
Description: Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
Study: NCT00661427

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 500 mg/m\^2 IV over 2 hours every other week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab 750 mg/m\^2 IV over 3 hours every other week
Study: NCT02093195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort turbuhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort turbuhaler
Study: NCT02973438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
Study: NCT01892839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low dialysate flow, smaller dialyzer
Description: The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dialysate flow, larger dialyzer
Description: The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
Study: NCT04291989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device
Description: This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
Study: NCT03726229

Intervention type: DEVICE
Intervention: Cholate assay
Description: Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
Study: NCT04137939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart exercise system
Description: The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
Study: NCT02110459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study: NCT00085735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard volume boost (whole posterior fossa radiation therapy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard volume boost (whole posterior fossa radiation therapy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard volume boost (whole posterior fossa radiation therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04294810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT02110459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study: NCT01358955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group cognitive intervention
Description: The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
Study: NCT02544685

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probio-Fix Inum
Description: Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beneo Synergy 1
Description: Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage regimen as active drugs
Study: NCT01432691

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemi (hemialloplastik)
Description: THA vs hemi
Study: NCT02505880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local anesthetic + Hypnosis
Description: Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
Study: NCT03466177

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive, multimodal retinal imaging
Description: Ocular exam including the application of different non-invasive ocular imaging techniques
Study: NCT04675866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Albumin-bound paclitaxel, S-1
Description: Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
Study: NCT03074474

Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex 1S Permanent
Description: OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
Study: NCT02179333

Intervention type: OTHER
Intervention: Ataxia rating scale
Description: Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
Study: NCT02173743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet enriched autologous blood plasma

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Regular barbotage/care as usual
Study: NCT02882659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Killer Cell (DKC)
Description: DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
Study: NCT00730639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX-1106)
Description: Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
Study: NCT02189850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 - Dose 1
Description: BLI800 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800 - Dose 2
Description: BLI800 oral solution
Study: NCT01836783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnion Allograft
Description: Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
Study: NCT04011280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
Study: NCT03183882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Feedback
Description: One-time summary report of their individual history of opioid prescribing over the past 14 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Normative Comparison Feedback
Description: One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
Study: NCT03270865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAF (Positioning And Fixation device)
Description: Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes.
Study: NCT02222259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA and Integrated Care Plan
Description: The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
Study: NCT04358835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: 4:1 ratio enteral ketogenic formula within 48 hours of intubation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: standard of care/supportive therapy
Study: NCT01988610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 28 days treatment with Mifepristone.
Study: NCT01387243

Intervention type: DRUG
Intervention: Orlistat
Description: 60 mg
Study: NCT02567487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Transversus abdominis plane block with levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Transversus abdominis plane block with levobupivacaine